Harbour BioMed (HBM), a Shanghai-based global biopharmaceutical company specialising in novel antibody therapeutics for immunology and oncology, has announced a strategic artificial intelligence (AI) collaboration with Evinova, a global health-tech company within the AstraZeneca Group. The partnership aims to harness AI and digital technologies to enhance the efficiency of innovative biologics development.

Under the agreement, Harbour BioMed and Evinova China will combine their respective strengths to build an open ecosystem for AI-driven drug research and development.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, "We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world." 

Nate Zhang, General Manager of Evinova China, added, "Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes. To realise our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harbouring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world."

The collaboration represents another step forward in Harbour BioMed’s strategy to integrate AI into biologics research and strengthen its global R&D capabilities.